Inhibition of ATAD3A was shown to restore sensitivity to sorafenib by disrupting the mitophagic process, suggesting that targeting this pathway could provide a novel therapeutic strategy for patients with HCC who exhibit resistance to standard treatments (41). This evidence concerns the gene ATAD3A and hepatocellular carcinoma.